| Literature DB >> 29067015 |
Carlos Fernando O R Melo1, Jeany Delafiori1, Diogo N de Oliveira1, Tatiane M Guerreiro1, Cibele Z Esteves1, Estela de O Lima1, Victoria Pando-Robles2, Rodrigo R Catharino1.
Abstract
Zika virus (ZIKV) infection has recently emerged as a major concern worldwide due to its strong association with nervous system malformation (microcephaly) of fetuses in pregnant women infected by the virus. Signs and symptoms of ZIKV infection are often mistaken with other common viral infections. Since transmission may occur through biological fluids exchange and coitus, in addition to mosquito bite, this condition is an important infectious disease. Thus, understanding the mechanism of viral infection has become an important research focus, as well as providing potential targets for assertive clinical diagnosis and quality screening for hemoderivatives. Within this context, the present work analyzed blood plasma from 79 subjects, divided as a control group and a ZIKV-infected group. Samples underwent direct-infusion mass spectrometry and statistical analysis, where eight markers related to the pathophysiological process of ZIKV infection were elected and characterized. Among these, Angiotensin (1-7) and Angiotensin I were upregulated under infection, showing an attempt to induce autophagy of the infected cells. However, this finding is concerning about hypertensive individuals under treatment with inhibitors of the Renin-Angiotensin System (RAS), which could reduce this response against the virus and exacerbate the symptoms of the infection. Moreover, one of the most abundant glycosphingolipids in the nervous tissue, Ganglioside GM2, was also elected in the present study as an infection biomarker. Considered an important pathogen receptor at membrane's outer layer, this finding represents the importance of gangliosides for ZIKV infection and its association with brain tropism. Furthermore, a series of phosphatidylinositols were also identified as biomarkers, implying a significant role of the PI3K-AKT-mTOR Pathway in this mechanism. Finally, these pathways may also be understood as potential targets to be considered in pharmacological intervention studies on ZIKV infection management.Entities:
Keywords: Zika virus; mass spectrometry; metabolomics; viromics
Year: 2017 PMID: 29067015 PMCID: PMC5641361 DOI: 10.3389/fmicb.2017.01954
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Demographics and clinical conditions of all recruited and included individuals in the study.
| RT-PCR exam | Negative | Negative | Positive |
| Symptomatic? | No | Yes | Yes |
| Male | 6 | 25 | 27 |
| Female | 4 | 9 | 8 |
| Mean age (median) | 32.76 (30) | 31.67 (30) | 35.45 (35) |
| Fever (%) | NA | 17.14 | 29.40 |
| Rash (%) | NA | 20.00 | 41.18 |
| Joint pain (%) | NA | 2.86 | 11.76 |
| Retro-orbital pain (%) | NA | 5.71 | 5.88 |
| Migraine (%) | NA | 8.57 | 17.60 |
| Conjunctivitis (%) | NA | 14.29 | 17.60 |
| Neurological syndrome (%) | NA | 17.14 | 8.80 |
NA, Not Applicable.
Figure 1Establishment of the OPLS-DA model. The figure illustrates the score plot of OPLS-DA modeling for serum metabolomics data on positive and negative mode. The non-infected serum group clustered to the left region and the infected serum group clustered to the right area in the both positive and negative modes. The shaded area shows represents the confidence interval of 95% from OPLS-DA models; the T score [1] shows the relevance of the predictive component [1] in explaining the clustering model.
Lipid markers elected by OPLS-DA from serum analysis of patients infected with Zika Virus (ZIKV group).
| 977.4949 | 977.4929 | 2.04 | [M+Cl]− | 61356 | PIP(18:1/18:1) and/or |
| 61365 | PIP(18:2/18:0) and/or | ||||
| 61384 | PIP(20:2/16:0) | ||||
| 933.4374 | 933.4355 | 2.03 | [M+Cl]− | 71112 | Angiotensin (1-7) |
| 963.4985 | 963.5005 | −2.07 | [M-H]− | 61399 | PIP(20:4/18:1) and/or |
| 61395 | PIP(20:3/18:2) and/or | ||||
| 61403 | PIP(20:4/18:1) and/or | ||||
| 61319 | PIP(16:0/22:5) and/or | ||||
| 61405 | PIP(22:3/16:2) | ||||
| 949.4635 | 949.4616 | 2.00 | [M+Cl]− | 61326 | PIP(16:2/18:0) and/or |
| 61323 | PIP(16:1/18:1) and/or | ||||
| 61364 | PIP(18:2/16:0) | ||||
| 975.4792 | 975.4772 | 2.05 | [M+Cl]− | 61366 | PIP(18:2/18:1) and/or |
| 61374 | PIP(18:3/18:0) and/or | ||||
| 61386 | PIP(20:3/16:0) | ||||
| 1073.5125 | 1073.5103 | 2.04 | [M+Na]+ | 61492 | PIP2(20:0/18:2) and/or |
| 61495 | PIP2(20:1/18:1) and/or | ||||
| 61498 | PIP2(20:2/18:0) and/or | ||||
| 61423 | PIP2(16:0/22:2) | ||||
| 1296.6822 | 1296.6848 | −2.01 | [M+H]+ | 65540 | Angiotensin I |
| 1323.7423 | 1323.7395 | 2.11 | [M+Na]+ | 62596 | Ganglioside GM2 (d18:0/12:0) |
METLIN ID.
Figure 2High-resolution mass spectrum of patients' serums on the negative ion mode: asymptomatic individuals with negative PCR results, patients with clinical manifestations of Zika virus infection and negative diagnosis by PCR, and patients with clinical manifestations of Zika virus infection and diagnosis Positive by PCR.
Figure 3High-resolution mass spectrum of patients' serum on the positive mode: asymptomatic individuals with negative PCR results, patients with clinical manifestations of Zika virus infection and negative diagnosis by PCR, and patients with clinical manifestations of Zika virus infection and diagnosis Positive by PCR.
Figure 4Cell signaling pathway scheme of metabolic alterations due to Zika virus infection. The scheme shows the cell response, attempting to control the viral infection, with Ang I or II, Ang 1-9, and Ang 1-7 signaling to activate the autophagy process, which would lead to cell death and, consequently, decreased viral replication. It is also possible to see the close participation of lipids PI, PIP2, and PIP3 as key players in this process, all of which were elected as biomarkers. The scheme also shows the inhibition of AKT by the viral proteins of ZIKV (solid and dashed red lines), which culminates in the inhibition of autophagy, so that replication can occur. In a parallel mechanism, it is possible to see that the same pathway is responsible for the inhibition of neurogenesis. Ang I/II, Angiotensin I/II; Ang 1-9, Angiotensin 1-9; Ang 1-7, Angiotensin 1-7; MAS1, MAS receptor; PI, 1-Phosphatidyl-D-myo-inositol; PIP, Phosphatidylinositol 5-phosphate; PIP2, Phosphatidylinositol-4,5-bisphosphate; PIP3, Phosphatidylinositol-3,4,5-trisphosphate; PDK1, 3-phosphoinositide-dependent protein kinase 1; AKT, AKT serine/threonine kinase 3; mTOR, mechanistic target of rapamycin (atypical serine/threonine kinase); PIKFYVE, 1-phosphatidylinositol-3-phosphate 5-kinase; PIP4K, phosphatidylinositol-5-phosphate 4-kinase type 2 alpha; PIK3C, phosphoinositide-3-kinase regulatory subunit 5; PIK3, phosphoinositide-3-kinase regulatory; ACE2, angiotensin-converting enzyme 2; CTSA, carboxypeptidase C; CPA3, carboxypeptidase A3; ACE, angiotensin-converting enzyme; MME, Neprilysin.